CEST MRI of 3-O-methyl-D-glucose uptake and accumulation in brain tumors

Akansha Ashvani Sehgal, Yuguo Li, Bachchu Lal, Nirbhay N. Yadav, Xiang Xu, Jiadi Xu, John J Laterra, Peter C Van Zijl

Research output: Contribution to journalArticle

Abstract

Purpose: 3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose. Methods: Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). Results: Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0%, while it was 1.5-3.5% in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0% and 0.5-1.5% in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan. Conclusions: 3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.

Original languageEnglish (US)
JournalMagnetic Resonance in Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

3-O-Methylglucose
Brain Neoplasms
Contrast Media
Glucose
Neoplasms
Brain
Heterografts
Glioma
Intravenous Injections
Cell Line

Keywords

  • 3-O-methyl glucose
  • brain tumor
  • CEST imaging
  • contrast enhancement

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

CEST MRI of 3-O-methyl-D-glucose uptake and accumulation in brain tumors. / Sehgal, Akansha Ashvani; Li, Yuguo; Lal, Bachchu; Yadav, Nirbhay N.; Xu, Xiang; Xu, Jiadi; Laterra, John J; Van Zijl, Peter C.

In: Magnetic Resonance in Medicine, 01.01.2018.

Research output: Contribution to journalArticle

@article{fbffa9f5609441648912de663cd1bd93,
title = "CEST MRI of 3-O-methyl-D-glucose uptake and accumulation in brain tumors",
abstract = "Purpose: 3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose. Methods: Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). Results: Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0{\%}, while it was 1.5-3.5{\%} in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0{\%} and 0.5-1.5{\%} in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan. Conclusions: 3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.",
keywords = "3-O-methyl glucose, brain tumor, CEST imaging, contrast enhancement",
author = "Sehgal, {Akansha Ashvani} and Yuguo Li and Bachchu Lal and Yadav, {Nirbhay N.} and Xiang Xu and Jiadi Xu and Laterra, {John J} and {Van Zijl}, {Peter C}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/mrm.27489",
language = "English (US)",
journal = "Magnetic Resonance in Medicine",
issn = "0740-3194",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - CEST MRI of 3-O-methyl-D-glucose uptake and accumulation in brain tumors

AU - Sehgal, Akansha Ashvani

AU - Li, Yuguo

AU - Lal, Bachchu

AU - Yadav, Nirbhay N.

AU - Xu, Xiang

AU - Xu, Jiadi

AU - Laterra, John J

AU - Van Zijl, Peter C

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: 3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose. Methods: Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). Results: Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0%, while it was 1.5-3.5% in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0% and 0.5-1.5% in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan. Conclusions: 3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.

AB - Purpose: 3-O-Methyl-D-glucose (3-OMG) is a nonmetabolizable structural analog of glucose that offers potential to be used as a CEST-contrast agent for tumor detection. Here, we explore it for CEST-detection of malignant brain tumors and compare it with D-glucose. Methods: Glioma xenografts of a U87-MG cell line were implanted in five mice. Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). Results: Tumor regions showed higher enhancement as compared to contralateral brain. The CEST contrast enhancement in the tumor region ranged from 2.5-5.0%, while it was 1.5-3.5% in contralateral brain. Previous D-glucose studies of the same tumor model showed an enhancement of 1.5-3.0% and 0.5-1.5% in tumor and contralateral brain, respectively. The signal gradually stabilized to a value that persisted for the length of the scan. Conclusions: 3-OMG shows a CEST contrast enhancement that is approximately twice as much as that of D-glucose for a similar tumor line. In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors.

KW - 3-O-methyl glucose

KW - brain tumor

KW - CEST imaging

KW - contrast enhancement

UR - http://www.scopus.com/inward/record.url?scp=85053409813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053409813&partnerID=8YFLogxK

U2 - 10.1002/mrm.27489

DO - 10.1002/mrm.27489

M3 - Article

C2 - 30206994

AN - SCOPUS:85053409813

JO - Magnetic Resonance in Medicine

JF - Magnetic Resonance in Medicine

SN - 0740-3194

ER -